$10B+
Projected IgAN market
Premium Category Domain
Submit an offer →
IgAN.com
The exact, four-letter .com that defines the IgA nephropathy category — a $10B+ emerging market with seven branded therapies competing for the prescriber, payer, and patient relationship. A once-available digital asset for any company building a brand, patient resource, or HCP destination in IgAN.
Asking price
$229,000USD · serious offers considered
$4.9B
Vertex–Alpine deal (single IgAN asset)
$390K–$583K
Annual WAC, approved IgAN therapies
7
Branded molecules in or approaching market
Why IgAN, why now
IgA nephropathy is the most common primary glomerulonephritis worldwide and one of the fastest-evolving rare-kidney-disease categories in pharma. After decades with only supportive care, a permissive FDA accelerated-approval pathway has unlocked a wave of disease-modifying therapies — and the digital real estate that defines the category is finite.
$10B+
Total addressable market
Sell-side analysts project IgAN as a $10B+ market once disease-modifying BAFF/APRIL therapies move earlier in the treatment paradigm.
~48K · US
Treatable US patients
US patients with persistent proteinuria — the addressable population for next-generation IgAN therapy. ~384K globally.
80%
Patients age 16–35
The IgAN population skews young, digitally native, and treatment-naïve — uniquely receptive to direct-to-patient brand and education.
"IgAN is a $10B+ market primed for effective therapies."— Sell-side biotech analyst preview, February 2026
An active, competitive category
Seven branded molecules from leading pharma and biotech are now competing for IgAN market share. Brand differentiation, patient experience, and digital engagement will increasingly define the winners.
| Molecule | Company | Status |
|---|---|---|
| Sibeprenlimab (Voyxact) | Otsuka / Visterra | Approved 2025 |
| Iptacopan (Fabhalta) | Novartis | Approved 2024 |
| Povetacicept | Vertex (acq. Alpine) | Phase 3 · RAINIER |
| Atacicept | Vera Therapeutics | Phase 3 · ORIGIN 3 |
| Telitacicept | Vor / RemeGen | Phase 3 · TELIGAN |
| Zigakibart | Novartis (acq. Chinook) | Phase 3 · BEYOND |
| Felzartamab | Biogen | Phase 3 · PREVAIL |
Sources: company filings, FDA approvals, ClinicalTrials.gov registrations. Status as of February 2026.
The category attracts billion-dollar bets
Recent transactions confirm what BD teams already know: in IgAN, the asset is the molecule — and the brand is the moat.
$4.9B
Vertex acquires Alpine
April 2024. Vertex's largest acquisition ever, paid almost entirely for povetacicept's IgAN potential while still in Phase 2.
$3.2B
Novartis acquires Chinook
2023. A single-asset IgAN deal (zigakibart) that established category precedent for premium acquisition multiples.
$583K
Per-patient annual WAC
Fabhalta's 2026 IgAN WAC. Voyxact at ~$390K. These are luxury-pharma economics — every patient relationship matters.
What you're acquiring
-
✓
The exact disease acronym, in .com. IgAN is the universally used clinical and patient shorthand for IgA nephropathy. Four letters. No substitutes. Permanent scarcity.
-
✓
Direct-navigation traffic from a digitally native audience. 80% of IgAN patients are diagnosed between ages 16 and 35 — the demographic most likely to type "igan.com" directly into the browser.
-
✓
A defensible brand anchor across uses. Suitable as a corporate, product, disease-education, patient-services, or HCP destination — with redirect flexibility to existing properties.
-
✓
Strategic value vs. competitor positioning. With seven branded therapies competing in a single category, owning the category-defining .com is a uniquely durable form of differentiation.
-
✓
Clean ownership, ready for transfer. Privately held, never operated commercially, no encumbrances. Transferable via standard escrow within 5–7 business days.
How acquisition works
1. Submit interest
Email sales@igan.com. All inquiries are handled directly and confidentially. NDAs available on request.
2. Negotiate terms
Asking price is $229,000. Serious offers considered. Net of marketplace fees if applicable.
3. Escrow & transfer
Closing through Escrow.com or comparable. Typical transfer to a new registrar completes within 5–7 business days.
Inquire about IgAN.com
All inquiries are handled directly and confidentially by the owner.
sales@igan.com
Direct, confidential, monitored daily.
Email sales@igan.com →NDAs available on request. Please identify your organization to receive a substantive response.